Alzheimer s Research & Therapy · 2025 · 123 citations · 39 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyNeurodegenerationNeuropharmacologyDementia PharmacotherapyGlucagon-like Peptide-1 Receptor AgonistsNeurodegenerative Disease PharmacotherapyNeurodegenerative DiseasesNeuroinflammationNeuroprotectionGlucagon-like Peptide 1 Receptor AgonismGlucagon-like Peptide 1 SignalingGlucagon-like Peptide-1 Receptor SignalingNeuroprotective AgentsNeuroprotective PharmacotherapyNeuroprotective ResponsesPharmacological Treatment Of DementiaPlacebo-controlled Efficacy Assessment
BACKGROUND: Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer's disease (AD), including neuroinflammation, represent potentially important and novel approaches. The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes and obesity and has an established safety profile. Semaglutide may have a disease-modifying, neuroprotective effect in AD through multimodal mechanisms including neuroinflammatory, vascular, and other AD-related processes. Large randomized controlled trials are needed to assess the efficacy and safety of semaglutide in early-stage symptomatic AD. METHODS: evoke and evoke+ are randomized, double-blind, placebo-controlled phase 3 trials investigating the efficacy, safety, and tolerability of once-daily oral semaglutide versus placebo in early-stage symptomatic AD. Eligible participants were men or women aged 55-85 years with mild cognitive impairment or mild dementia due to AD with confirmed amyloid abnormalities (assessed by positron emission tomography or cerebrospinal fluid [CSF] analysis). After a maximum 12-week screening phase, an anticipated 1840 patients in each trial are randomized (1:1) to semaglutide or placebo for 156 weeks (104-week main treatment phase and 52-week extension). Randomized participants follow an 8-week dose escalation regimen (3 mg [weeks 0-4], 7 mg [weeks 4-8], and 14 mg [weeks 8-156]). The primary endpoint is the semaglutide-placebo difference on change from baseline to week 104 in the Clinical Dementia Rating - Sum of Boxes score. Analyses of plasma biomarkers, collected from all participants, and a CSF sub-study (planned n = 210) will explore semaglutide effects on AD biomarkers and neuroinflammation. RESULTS: Enrollment was undertaken between May 18, 2021, and September 8, 2023. Completion of the trials' main phase is expected in September 2025, and the 52-week extension (in which participants and investigators remain blinded to treatment assignment) will continue to October 2026. CONCLUSION: evoke and evoke+ are the first large-scale trials to investigate the disease-modifying potential of semaglutide in participants with early-stage symptomatic AD, including exploration of effects on AD biomarkers and neuroinflammation. The trials will provide data on the potential disease-modifying effects of semaglutide and will be important in evaluating its utility in the treatment of early-stage symptomatic AD. TRIAL REGISTRATION: Clinicaltrials.gov, NCT04777396 and NCT04777409. Date: 02/03/2021.
39
The Clinical Dementia Rating (CDR)
John C. Morris · Neurology · 1993 · 10K citations
Medicine, Neurology, Psychiatry +12
The Lancet · 2021 · 4.9K citations · Full text
Life Sciences, Genetics, Neurology +17
Donanemab in Early Symptomatic Alzheimer Disease
John R. Sims, Jennifer A. Zimmer, Cynthia Evans et al. · JAMA · 2023 · 2.6K citations · Full text
Medicine, Neurology, Neuroscience +17
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Céline Bellenguez, Fahri Küçükali, Iris E. Jansen et al. · Nature Genetics · 2022 · 2.5K citations · Full text